Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study

被引：30

作者：

Roussel, Ronan ^{[1
]}

Darmon, Patrice ^{[2
]}

Pichelin, Matthieu ^{[3
]}

Goronflot, Thomas ^{[4
]}

Abouleka, Yawa ^{[1
]}

Ait Bachir, Leila ^{[5
]}

Allix, Ingrid ^{[6
]}

Ancelle, Deborah ^{[7
]}

Barraud, Sara ^{[8
,9
]}

Bordier, Lyse ^{[10
]}

Carlier, Aurelie ^{[1
]}

Chevalier, Nicolas ^{[11
,12
]}

Coffin-Boutreux, Christine ^{[13
]}

Cosson, Emmanuel ^{[14
,15
,16
]}

Dorange, Anne ^{[17
]}

Dupuy, Olivier ^{[18
]}

Fontaine, Pierre ^{[19
]}

Fremy, Benedicte ^{[20
]}

Galtier, Florence ^{[21
,22
]}

Germain, Natacha ^{[23
,24
]}

Guedj, Anne-Marie ^{[25
]}

Larger, Etienne ^{[26
]}

Laugier-Robiolle, Stephanie ^{[27
]}

Laviolle, Bruno ^{[28
]}

Ludwig, Lisa ^{[29
]}

Monier, Arnaud ^{[30
]}

Montanier, Nathanaelle ^{[31
]}

Moulin, Philippe ^{[32
]}

Moura, Isabelle ^{[33
]}

Prevost, Gaetan ^{[34
]}

Reznik, Yves ^{[35
]}

Sabbah, Nadia ^{[36
]}

Saulnier, Pierre-Jean ^{[37
]}

Serusclat, Pierre ^{[38
]}

Vatier, Camille ^{[39
,40
]}

Wargny, Matthieu ^{[4
]}

Hadjadj, Samy ^{[3
]}

Gourdy, Pierre ^{[41
]}

Cariou, Bertrand ^{[3
]}

机构：

[1] Hop Bichat Claude Bernard, AP HP, Ctr Rech Cordeliers, INSERM,Dept Endocrinol Diabetol & Nutr, Paris, France

[2] Aix Marseille Univ, Hop Concept, Serv Endocrinol Malad Metab & Nutr, AP HM,INSERM,INRA,C2VN, Marseille, France

[3] Univ Nantes, CHU Nantes, Dept Endocrinol Diabetol & Nutr, Inst Thorax,INSERM,CNRS, Nantes, France

[4] CHU Nantes, Clin Donnees, CIC EC 1413, Nantes, France

[5] Hop Franco Britannique, Dept Endocrinol, Diabetol, Nutr, Levallois Perret, France

[6] CHU Angers, Dept Endocrinol, Diabetol, Nutr, Angers, France

[7] CH Le Havre, Dept Endocrinol, Diabetol, Nutr, Le Havre, France

[8] Univ Reims, UFR Sci Exactes & Nat, CRESTIC, EA 3804, Moulin Housse, Reims, France

[9] CHU Reims, Serv Endocrinol Diabete Nutr, Reims, France

[10] Hop Instruct Armees Begin, Serv Sante Armees, Dept Endocrinol, Malad Metab, St Mande, France

[11] Univ Cote dAzur, CHU Nice, Hop Archet 2, Serv Endocrinol Diabetol & Med Reprod, Nice, France

[12] Univ Cote dAzur, CHU Nice, INSERM, UMR U1065,UNS, Nice, France

[13] CH Perigueux, Dept Endocrinol, Diabetol, Malad Metab, Perigueux, France

[14] CINFO Hop Avicenne, AP HP, CRNH IdF, Dept Endocrinol Diabetol & Nutr, Bobigny, France

[15] INSERM, UMR U557, Bobigny, France

[16] Univ Paris 13, Sorbonne Paris Cite, Bobigny, France

[17] CH Le Mans, Dept Diabetol, Endocrinol, Le Mans, France

[18] Paris Hop St Joseph, Dept Endocrinol, Diabetol, Paris, France

[19] Univ Lille, Hop Huriez, Dept Endocrinol Diabete & Malad Metab, Lille, France

[20] CH Agen Nerac, Dept Endocrinol, Diabetol, Nutr, Agen, Lot & Garonne, France

[21] CHU Montpellier, Hop St Eloi, Ctr Invest Clin, Montpellier, France

[22] CHU Montpellier, Hop St Eloi, Dept Malad Endocriniennes, INSERM,CIC 1411, Montpellier, France

[23] CHU St Etienne, Dept Endocrinol, St Etienne, France

[24] Univ Jean Monnet, TAPE Res Grp, EA 7423, St Etienne, France

[25] CHU Nimes, Dept Malad Metab & Endocriniennes, Nimes, France

[26] Ctr Univ Paris, Hop Cochin, AP HP, Serv Diabetol, Paris, France

[27] CH Auch, Dept Diabetol, Auch, France

[28] Univ Rennes, CHU Rennes, INSERM, CIC 1414 Ctr Invest Clin Rennes, Rennes, France

[29] Univ Lorraine, CHRU Nancy, Hop Brahois, Nancy, France

[30] CH CHARTRES, Dept Diabetol, Endocrinol, Nutr, Chartres, Eure & Loir, France

[31] CH Forez, Dept Med, Forez, France

[32] Univ Lyon 1, Hosp Civils Lyon, Fedarat Endocrinol Malad Metab Diabete & Nutr, INSERM,CARMEN,UMR 1060, Lyon, France

[33] CH Albi, Unite Transversale Diabetol Endocrinol, Albi, France

[34] Univ Rouen, CHU Rouen, Dept Endocrinol Diabetol & Malad Metab, Rouen, France

[35] CHU Caen, Dept Diabetol, Caen, France

[36] CH Cayenne, Dept Endocrinol, Diabetol, Nutr, Cayenne, France

[37] Univ Poitiers, CHU Poitiers, INSERM, Ctr Invest Clin CIC 1402, Poitiers, France

[38] Grp Hosp Mutualiste Portes Sud, Dept Endocrinol Diabetol & Nutr, Venissieux, France

[39] St Antoine Hosp, AP HP, Ctr Reference Rare Dis Insulin Secret & Insulin S, Dept Endocrinol, Paris, France

[40] Sorbonne Univ, Ctr Rech St Antoine, INSERM, UMRS 938, Paris, France

[41] Univ Toulouse, CHU Toulouse, Dept Endocrinol Diabetol & Nutr, INSERM,UPS,Inst Malad Metab & Cardiovasc,UMR1048, Toulouse, France

来源：

DIABETES OBESITY & METABOLISM | 2021年 / 23卷 / 05期

关键词：

DPP-4; inhibitor; observational study; type; 2; diabetes; RISK; INFECTIONS; DISEASE;

D O I：

10.1111/dom.14324

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aim: To investigate the association between routine use of dipeptidyl peptidase-4 (DPP-4) inhibitors and the severity of coronavirus disease 2019 (COVID-19) infection in patient with type 2 diabetes in a large multicentric study. Materials and Methods: This study was a secondary analysis of the CORONADO study on 2449 patients with type 2 diabetes (T2D) hospitalized for COVID-19 in 68 French centres. The composite primary endpoint combined tracheal intubation for mechanical ventilation and death within 7 days of admission. Stabilized weights were computed for patients based on propensity score (DPP-4 inhibitors users vs. non-users) and were used in multivariable logistic regression models to estimate the average treatment effect in the treated as inverse probability of treatment weighting (IPTW). Results: Five hundred and ninety-six participants were under DPP-4 inhibitors before admission to hospital (24.3%). The primary outcome occurred at similar rates in users and non-users of DPP-4 inhibitors (27.7% vs. 28.6%; p = .68). In propensity analysis, the IPTW-adjusted models showed no significant association between the use of DPP-4 inhibitors and the primary outcome by Day 7 (OR [95% CI]: 0.95 [0.77-1.17]) or Day 28 (OR [95% CI]: 0.96 [0.78-1.17]). Similar neutral findings were found between use of DPP-4 inhibitors and the risk of tracheal intubation and death. Conclusions: These data support the safety of DPP-4 inhibitors for diabetes management during the COVID-19 pandemic and they should not be discontinued.

引用

页码：1162 / 1172

页数：11

共 33 条

[1] Propensity scores based methods for estimating average treatment effect and average treatment effect among treated: A comparative study [J].